Notice: Spironolactone in short supply
On this page
Background
Spironolactone is a drug used in the diagnosis of primary hyperaldosteronism. It is also used in the treatment of nephrotic syndrome, hypertension, hypokalemia, and edematous conditions related to congestive heart failure and cirrhosis of the liver.
In Canada, Spironolactone is marketed by Teva Canada Ltd, Jamp Pharma Corporation, Mint Pharmaceuticals and Pfizer Canada ULC in 25 mg and 100 mg strengths.
Teva Canada Ltd and Mint Pharmaceuticals are reporting shortages because of manufacturing disruptions, and Pfizer Canada ULC is reporting a shortage because of increased demand. As a result, Spironolactone may not always be available.
What we're doing
We recognize the importance of Spironolactone for patients. Addressing this shortage is a top priority.
We're communicating with health care providers and provincial and territorial governments to coordinate the sharing of information about this shortage.
We're also working with manufacturers and stakeholders to monitor the supply of Spironolactone, and looking at options to increase access to these products.
Health care providers can get guidance to help manage this shortage from the Canadian Cardiovascular Society, Canadian Heart Failure Society, Canadian Society of Healthcare-Systems Pharmacy and the Canadian Pharmacists Association.
What you can do
Speak to your doctor or pharmacist if you have questions or concerns about this shortage. They may be able to offer other options if your medication is not available.
You should always:
- use a licensed pharmacy to get your medication
- only buy products that are authorized for sale in Canada
- avoid buying products from unlicensed and unverified online sellers, as these products may:
- not contain the active ingredient
- contain other undeclared and hazardous ingredients that could cause serious risks to health
- not meet manufacturing quality and safety standards, and have unknown contaminants
All drugs approved for sale in Canada have an 8-digit drug identification number (DIN). The DIN assures you that Health Canada has assessed a drug and considers it safe and effective when used as directed on the label. The DIN also provides a way to track adverse drug reactions.
Report any health product-related side effects or complaints to Health Canada.
Check this web page regularly as we will update it if new information becomes available.
Learn more about drug shortages in Canada and how Canadians can deal with drug shortages.